Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer
Drug Design, Development and Therapy · 2026
DOI: 10.2147/dddt.s576346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Yueting Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Urological Diseases, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Gua…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Immunotherapy, HLA-A2 Antigen, Glutamate Carboxypeptidase II. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Urological Diseases, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
- Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pharmacology and International Cancer Center, Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China.
ORCID-Profile: Yanni Xie, Xiaolu Duan
Zitieren
APA
Huang, Y., Yang, Y., Xie, Y., Shu, Y., Yang, S., Long, X., Wen, Z., Duan, X., Fu, L., Gu, D., & Huang, T. (2026). Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s576346
Vancouver
Huang Y, Yang Y, Xie Y, Shu Y, Yang S, Long X, et al. Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s576346
BibTeX
@article{Huang2026,
author = {Huang, Yueting and Yang, Yang and Xie, Yanni and Shu, Yue and Yang, Siqi and Long, Xuezhi and Wen, Zhipeng and Duan, Xiaolu and Fu, Li and Gu, Di and Huang, Tuxiong},
title = {Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer},
journal = {Drug Design, Development and Therapy},
year = {2026},
doi = {10.2147/dddt.s576346}
}
EUVIMED